EPISODE · Jan 14, 2019 · 9 MIN
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY) - Jan '19 update
from Stock Day Media · host Stock Day Media
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), rejoins the show to discuss recent additions to the board of directors, Pro 140's impact on cancer treatment, and plans for 2019. Colon Cancer # humanized monoclonal antibodies # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # Pro140 # leronlimap Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
What this episode covers
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), rejoins the show to discuss recent additions to the board of directors, Pro 140's impact on cancer treatment, and plans for 2019. Colon Cancer # humanized monoclonal antibodies # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # Pro140 # leronlimap Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
NOW PLAYING
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY) - Jan '19 update
No transcript for this episode yet
Similar Episodes
Sep 22, 2023 ·20m
Sep 22, 2023 ·20m
Sep 22, 2023 ·27m
Sep 22, 2023 ·14m
Sep 22, 2023 ·24m
Sep 22, 2023 ·22m